Back to today’s briefing

Story perspectives

BlackfinBio's Gene Therapy Gains FDA Approval for SPG47

5/11/2025

37 4

Summary

Story summary

BlackfinBio Limited, emerging from the University of Sheffield, has secured FDA approval for a groundbreaking Phase 1/2 trial of its AAV gene therapy, BFB-101. This innovative treatment targets Hereditary Spastic Paraplegia, Type 47 (SPG47), and will be tested for safety and effectiveness in children at Boston Children’s Hospital, offering hope for those affected by this rare neurological condition.

1 of 1

Story summary

BlackfinBio Limited, emerging from the University of Sheffield, has secured FDA approval for a groundbreaking Phase 1/2 trial of its AAV gene therapy, BFB-101. This innovative treatment targets Hereditary Spastic Paraplegia, Type 47 (SPG47), and will be tested for safety and effectiveness in children at Boston Children’s Hospital, offering hope for those affected by this rare neurological condition.